» Articles » PMID: 37061606

Estrogen Associates with Female Predominance in Xp11.2 Translocation Renal Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2023 Apr 15
PMID 37061606
Authors
Affiliations
Soon will be listed here.
Abstract

Based on the epidemiological characteristics of susceptibility and age selectivity for women in Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC), we inferred that estrogen was to be blamed. Rad54 like 2 (Rad54l2) which might be one of key effector proteins of DNA damage mediated by estrogen was downregulated in numerous cancers, however, its role in epidemiological characteristics of Xp11.2 tRCC was needed to further study. We reviewed 1005 Xp11.2 tRCC cases and collected estrogen data and then compared the onset time of Xp11.2 tRCC cases in female with estrogen changing trend. An RNA-sequencing was performed in estrogen treated HK-2 cells and subsequently bioinformatic analysis was applied based on the Cancer Genome Atlas (TCGA) and GEO database. The male-to-female ratio of Xp11.2 tRCC was 1:1.4 and the median age of onset was 29.7 years old. The onset trend of female was similar to estrogen physiological rhythm (r = 0.67, p < 0.01). In Xp11.2 tRCC and HK-2 cells after estrogen treatment, Rad54l2 was downregulated, and GSEA showed that pathways significantly enriched in DNA damage repair and cancer related clusters after estrogen treated, as well as GO and KEGG analysis. Downregulation of Rad54l2 was in numerous cancers, including renal cell carcinoma (RCC), in which Rad54l2 expression was significantly decreased in male, age over 60 years old, T2&T3&T4 stages, pathologic SII&SIII&SIV stages as well as histologic G3&G4 grades, and cox regression analysis proved that Rad54l2 expression was a risk factor for overall survival, disease-specific survival and progression-free interval in univariate analysis. There existed female predominance in Xp11.2 tRCC and Rad54l2 might play vital role in estrogen mediating female predominance in Xp11.2 tRCC.

Citing Articles

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

Incorvaia L, Marques Monteiro F, Massari F, Park S, Roviello G, Fiala O Cancer Immunol Immunother. 2024; 73(8):142.

PMID: 38832989 PMC: 11150359. DOI: 10.1007/s00262-024-03719-0.

References
1.
Epstein R, Smith P . Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res. 1988; 48(2):297-303. View

2.
Argani P, Zhong M, Reuter V, Fallon J, Epstein J, Netto G . TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol. 2016; 40(6):723-37. PMC: 4864095. DOI: 10.1097/PAS.0000000000000631. View

3.
Olde B, Leeb-Lundberg L . GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab. 2009; 20(8):409-16. DOI: 10.1016/j.tem.2009.04.006. View

4.
Sun L, Chao F, Luo B, Ye D, Zhao J, Zhang Q . Impact of Estrogen on the Relationship Between Obesity and Renal Cell Carcinoma Risk in Women. EBioMedicine. 2018; 34:108-112. PMC: 6116349. DOI: 10.1016/j.ebiom.2018.07.010. View

5.
Stapelfeld C, Dammann C, Maser E . Sex-specificity in lung cancer risk. Int J Cancer. 2019; 146(9):2376-2382. DOI: 10.1002/ijc.32716. View